Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Interventions to Improve Depressive Symptoms in Community-Dwelling Older Adults: A Scoping Review.

Journal of prevention (2022)·2026

Same author

Transcriptional regulatory network analysis uncovers modular gene control and potential key regulators in diabetic cardiomyopathy.

Frontiers in cell and developmental biology·2026

Same author

Trust By Design: Enabling Responsible Precision Health Through Blockchain-Powered Digital Twins And Trusted AI.

Blockchain in healthcare today·2026

Same author

Trust By Design: Enabling Responsible Precision Health Through Blockchain-Powered Digital Twins And Trusted AI.

Blockchain in healthcare today·2026

Same author

Dysregulated lncRNAs in Cisplatin-Induced Nephrotoxicity and Their Association with Apoptosis and Autophagy: An Exploratory In Vitro Study.

International journal of molecular sciences·2025

Same author

The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population.

Frontiers in oncology·2025

Same journal

Correction: Verde et al. Molecular Mechanisms of Protein Aggregation in ALS-FTD: Focus on TDP-43 and Cellular Protective Responses. <i>Cells</i> 2025, <i>14</i>, 680.

Cells·2026

Same journal

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype.

Cells·2026

Same journal

IL-4/IL-13-Driven Dysregulation of Epidermal Lipid Metabolism in Atopic Dermatitis: An Immunometabolic Link Between Type 2 Inflammation and Barrier Dysfunction.

Cells·2026

Same journal

Activity of DNA- and RNA-Guided Prokaryotic Argonautes in Human Mitochondria.

Cells·2026

Same journal

Placental Pathophysiology in Maternal Psychoactive Substance Use: Biological, Clinical, and Forensic Perspectives.

Cells·2026

Same journal

PACAP and Maxadilan (PAC1 Agonist) Influence Plaque Progression, Migratory Ability, and Mitochondrial Morphology and Dynamics in Vascular Smooth Muscle Cells.

Cells·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 4, 2026

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

Adenosine Depletion as A New Strategy to Decrease Glioblastoma Stem-Like Cells Aggressiveness.

Ignacio Niechi¹, Atenea Uribe-Ojeda², José Ignacio Erices³

¹Instituto de Bioquímica y Microbiología, Facultad de Ciencias, Universidad Austral de Chile, Valdivia 511-0566, Chile. ignacio.niechi@gmail.com.

|November 2, 2019

Summary

This summary is machine-generated.

Targeting adenosine with adenosine deaminase (ADA) reduces the aggressiveness of glioblastoma stem-like cells (GSCs). This approach offers a potential strategy to combat this aggressive brain tumor by decreasing GSC malignancy.

Keywords:

adenosine adenosine deaminase glioblastoma invasiveness stemness

More Related Videos

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Related Experiment Videos

Last Updated: Jan 4, 2026

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Area of Science:

Neuro-oncology
Cancer Stem Cell Biology
Biochemistry

Background:

Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis, driven by glioblastoma stem-like cells (GSCs).
GSCs overproduce extracellular adenosine, particularly under hypoxic conditions, which promotes their aggressiveness via HIF-2α signaling.
Adenosine's pathological effects can be counteracted by its degradation using adenosine deaminase (ADA).

Purpose of the Study:

To investigate the efficacy of adenosine depletion using recombinant ADA in reducing the malignancy of GSCs.
To assess the impact of ADA treatment on GSC migration, invasion, chemoresistance, and colony formation.

Main Methods:

Adenosine depletion in GSCs was achieved using recombinant ADA.
Cell migration and invasion assays (transwell and Matrigel-coated transwell) were employed.
Chemoresistance and colony formation assays were conducted to evaluate functional changes.

Main Results:

Treatment with ADA significantly decreased HIF-2α-dependent cell migration and invasion in GSCs under hypoxic conditions.
ADA treatment also reduced multidrug resistance protein (MRP)-mediated chemoresistance and colony formation capacity of GSCs.
Adenosine depletion effectively suppressed key aggressive phenotypes of GSCs.

Conclusions:

Adenosine depletion via ADA is a promising strategy to decrease glioblastoma stem-like cell aggressiveness.
Targeting adenosine signaling presents a potential therapeutic avenue for glioblastoma treatment.
ADA-mediated adenosine degradation may help overcome GSC-driven tumor progression and resistance.